JP2016536352A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536352A5
JP2016536352A5 JP2016547208A JP2016547208A JP2016536352A5 JP 2016536352 A5 JP2016536352 A5 JP 2016536352A5 JP 2016547208 A JP2016547208 A JP 2016547208A JP 2016547208 A JP2016547208 A JP 2016547208A JP 2016536352 A5 JP2016536352 A5 JP 2016536352A5
Authority
JP
Japan
Prior art keywords
medicament according
taxane
neutropenia
induced
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016547208A
Other languages
English (en)
Japanese (ja)
Other versions
JP6411523B2 (ja
JP2016536352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/085075 external-priority patent/WO2015051543A1/en
Publication of JP2016536352A publication Critical patent/JP2016536352A/ja
Publication of JP2016536352A5 publication Critical patent/JP2016536352A5/ja
Application granted granted Critical
Publication of JP6411523B2 publication Critical patent/JP6411523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016547208A 2013-10-11 2013-10-11 プリナブリン及びタキサンの組合せがん治療 Active JP6411523B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018179866A Division JP2018199726A (ja) 2018-09-26 2018-09-26 プリナブリン及びタキサンの組合せがん治療

Publications (3)

Publication Number Publication Date
JP2016536352A JP2016536352A (ja) 2016-11-24
JP2016536352A5 true JP2016536352A5 (Direct) 2017-01-05
JP6411523B2 JP6411523B2 (ja) 2018-10-24

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016547208A Active JP6411523B2 (ja) 2013-10-11 2013-10-11 プリナブリン及びタキサンの組合せがん治療

Country Status (18)

Country Link
US (2) US10596169B2 (Direct)
EP (1) EP3076972B1 (Direct)
JP (1) JP6411523B2 (Direct)
KR (1) KR102225371B1 (Direct)
CN (1) CN105705148B (Direct)
AU (1) AU2013402794B2 (Direct)
BR (1) BR112016007946A2 (Direct)
CA (1) CA2926771C (Direct)
DK (1) DK3076972T3 (Direct)
ES (1) ES2902665T3 (Direct)
IL (1) IL244984B (Direct)
MX (1) MX384751B (Direct)
MY (1) MY185650A (Direct)
NZ (1) NZ719049A (Direct)
RU (1) RU2662298C2 (Direct)
SG (1) SG11201602637QA (Direct)
WO (1) WO2015051543A1 (Direct)
ZA (1) ZA201602380B (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7243021B2 (ja) * 2015-02-12 2023-03-22 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 免疫チェックポイント阻害薬と併用するプリナブリンの使用
US10076518B2 (en) 2015-03-06 2018-09-18 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド プリナブリン組成物
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
EP3463337A4 (en) * 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
CN110381938A (zh) * 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
BR112020014960A2 (pt) 2018-01-24 2020-12-22 Beyondspring Pharmaceuticals, Inc. Composição e método para redução de trombocitopenia
BR112020015758A2 (pt) * 2018-02-01 2020-12-08 Beyondspring Pharmaceuticals, Inc. Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
CN113661253B (zh) * 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
CA3215047A1 (en) * 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
PT1529044E (pt) 2002-08-02 2008-01-14 Nereus Pharmaceuticals Inc Desidrofenila-histinas e os seus análogos e a síntese de desidrofenila-histinas e os seus análogos
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Similar Documents

Publication Publication Date Title
JP2016536352A5 (Direct)
JP4729503B2 (ja) 抗癌剤の奏効率増強剤
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2016530280A5 (Direct)
JP2014512356A5 (Direct)
JP2012522837A5 (Direct)
JP2017516802A5 (Direct)
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
JP2010528091A5 (Direct)
JP2014530181A5 (Direct)
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2015139515A (ru) Комбинированное лечение
JP2015510945A5 (Direct)
Chae et al. Retrospective analysis of efficacy and safety of oral paclitaxel for treatment of various cancers in dogs (2017–2021)
CN109419773B (zh) 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
JP2011500841A5 (Direct)
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients
Nair et al. Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation
CN106466306A (zh) 含维甲酸和索拉非尼的药物组合物及其应用
JP2015524467A5 (Direct)
JP2018199726A5 (Direct)
JP2006524678A (ja) 耐性乳癌の治療のためのイリノテカンの使用